Background
HIV-PULSE (HIV Proviral Unique molecular identifier mediated Long-read Sequencing) is a novel and cost-effective assay for near full-length (NFL) HIV-1 proviral sequencing. A detailed understanding of the viral reservoir is crucial for advancing curative efforts. This study explores the potential of HIV-PULSE to profile the HIV-1 reservoir in a high-throughput manner by analyzing key viral regions relevant to HIV-1 cure strategies.
Methods
HIV-PULSE was applied to 90 antiretroviral therapy-suppressed participants from the 2000HIV cohort (NTC03994835). NFL proviral sequences were profiled for intactness, drug resistance mutations (DRMs; protease, reverse transcriptase and integrase) and in silico sensitivity to immunotherapies like broadly neutralizing antibodies (bNAbs) and the clinical stage HIV-specific immune-mobilizing monoclonal T cell receptor therapy (IMC-M113V).
Results
A total of 4039 unique proviruses were obtained from 83 participants, of which 4% were considered intact. According to the Stanford HIV drug resistance database, across 2235 unique pol sequences, 268 harbored DRMs in 60 individuals. High-level resistance (HLR) was predicted in 39 participants, including 6 individuals with HLR to multiple drug classes. The majority of individuals with DRMs showed mutations associated with resistance to integrase strand transfer inhibitors (INSTIs; n=29), with HLR to first-generation INSTIs raltegravir (RAL) and elvitegravir (EVG) observed in 17 individuals. In 13 out of 20 participants with available pre-treatment plasma, HIV-PULSE revealed identical, similar or additional DRMs, demonstrating broader DRM detection in the archived reservoir than with plasma sequencing. Predicted sensitivity to 33 bNAbs across 2762 env sequences using the bNAb-ReP algorithm showed greater susceptibility among intact proviruses compared to defective ones (55% vs 29%), with bNAbs directed against CD4 binding sites demonstrating the highest predicted efficacy (70%). In addition, 72 out of 83 participants harbored Gag77-85 sequences (n=1180) predicted to be potential targets of IMC-M113V.
Conclusions
HIV-PULSE enables scalable, high-throughput profiling of NFL HIV-1 proviruses across the genome, simultaneously assessing archived DRMs and immune therapy sensitivity. By revealing reservoir composition and identifying targets for curative strategies, it represents a powerful platform for advancing HIV-1 cure research.